Short Interest in Humacyte, Inc. (NASDAQ:HUMAW) Drops By 48.1%

Humacyte, Inc. (NASDAQ:HUMAW) was the recipient of a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 2,071 shares, a drop of 48.1% from the February 12th total of 3,992 shares. Based on an average daily volume of 3,160 shares, the short-interest ratio is presently 0.7 days. Based on an average daily volume of 3,160 shares, the short-interest ratio is presently 0.7 days.

Humacyte Stock Performance

NASDAQ HUMAW traded down $0.03 on Thursday, hitting $0.09. 21,768 shares of the company’s stock were exchanged, compared to its average volume of 15,208. The firm’s 50-day moving average price is $0.12 and its two-hundred day moving average price is $0.17. Humacyte has a fifty-two week low of $0.08 and a fifty-two week high of $1.02.

About Humacyte

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.